Clinical Data

The T‑SPOT.TB  test is based on the in vitro ELISPOT assay developed at the University of Oxford, UK. The T‑SPOT.TB test also incorporates technology licensed from the Statens Serum Institut, Isis Innovation Limited, and Rutgers – the state university of New Jersey.

This pioneering technology has been described in over 300 peer-reveiwed publications showing the test’s excellent performance in a wide variety of clinical and epidemiological settings including:

  • Latent TB infection
  • TB disease (including pulmonary and extrapulmonary TB)
  • HIV positive and HIV negative patients
  • Anti-TNFα treated patients
  • Dialysis and transplant patients
  • Babies, children, adults and the elderly
  • Malnourished individuals
  • Low prevalence countries in the developed world and high prevalence countries in the developing world
  • Healthcare worker screening
  • New entrant screening

To see a summary of key clinical studies, please view our T-SPOT.TB Publications Summary.